当前血脂治疗指南比较分析:一切仍在变化
本文综述了ACC/AHA、CCS、ESC/EAS、USPSTF和VA/DoD五部血脂治疗指南的异同。所有指南均强调他汀用于动脉粥样硬化性心血管病一级和二级预防,并重视医患风险讨论,但在他汀强度、风险估算工具、特定亚组治疗及安全性考量上存在差异。临床医生应理解这些异同以指导他汀治疗决策。
要点
- 五部指南均推荐他汀用于ASCVD一级和二级预防。
- 指南间他汀强度、风险估算工具及特定亚组治疗存在差异。
- 临床决策应结合医患风险讨论并理解指南异同。
核心结论
- 当前五部主要血脂治疗指南在核心推荐上一致,但在他汀强度、风险估算工具、特定亚组治疗和安全性考量方面存在差异。
研究设计与样本
- 本文为对ACC/AHA、CCS、ESC/EAS、USPSTF和VA/DoD五部血脂治疗指南的比较分析综述。
主要发现
- 所有指南均采用严格的证据回顾,强调他汀用于ASCVD一级和二级预防,并重视医患风险讨论。
- 指南间差异体现在他汀强度、风险估算工具的使用、特定患者亚组的治疗以及安全性问题的考量。
临床怎么用
- 临床医生在考虑是否及如何对患者进行他汀治疗时,应理解当前和未来指南推荐中的相似性与差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lipid treatment guidelines have continued to evolve as new evidence emerges. We sought to review similarities and differences of 5 lipid treatment guidelines from the American College of Cardiology/American Heart Association, Canadian Cardiovascular Society, European Society for Cardiology/European Atherosclerosis Society, U.S. Preventive Services Task Force, and U.S. Veterans Affairs/Department of Defense. All guidelines utilize rigorous evidentiary review, highlight statin therapy for primary and secondary prevention of atherosclerotic cardiovascular disease, and emphasize a clinician-patient risk discussion. However, there are differences in statin intensities, use of risk estimators, treatment of specific patient subgroups, and consideration of safety concerns. Clinicians should understand these similarities and differences in current and future guideline recommendations when considering if and how to treat their patients with statin therapy.
引用
- Tibrewala A, Jivan A, Oetgen WJ, et al. A Comparative Analysis of Current Lipid Treatment Guidelines: Nothing Stands Still. J Am Coll Cardiol. 2018. PMID: 29447742. doi:10.1016/j.jacc.2017.12.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。